Immune cell-mediated antitumor activities of GD2-targeted liposomal c-myb antisense oligonucleotides containing CpG

Chiara Brignole1, Fabio Pastorino, Danilo Marimpietri

  • 1Laboratory of Oncology, Gaslini Children's Hospital, Genoa, Italy.

Abstract

Insights

Targeted liposomes with CpG-containing c-myb antisense oligonucleotides significantly improved survival in neuroblastoma models by activating immune cells like macrophages and NK cells.

Area of Science:

  • Immunology
  • Oncology
  • Nanotechnology

Background:

  • Neuroblastoma, a common infant cancer, involves c-myb proto-oncogene expression.
  • Disialoganglioside (GD2) is a tumor-associated antigen targeted by monoclonal antibodies.
  • Liposomes with anti-GD2 antibodies and c-myb antisense oligonucleotides show antitumor effects; CpG motifs can enhance immune responses.

Purpose of the Study:

  • To evaluate the antitumor efficacy of CpG-containing c-myb antisense oligonucleotides encapsulated within GD2-targeted liposomes.
  • To investigate the role of immune cell activation and cytokine release in the therapeutic response.

Main Methods:

  • Encapsulation of antisense (myb-as) and control (myb-scr) oligonucleotides with CpG motifs into targeted and non-targeted liposomes.
  • Establishment of murine neuroblastoma xenograft models (nude and SCID-bg).
  • Intravenous administration of liposome formulations and assessment of survival, immune cell activation, and cytokine profiles.

Main Results:

  • Targeted liposomes with CpG-myb-as significantly increased survival compared to other groups.
  • Immune cell activation (macrophages, B cells, NK cells) and increased IL-12 and IFN-gamma levels were observed, dependent on CpG motifs.
  • Antitumor activity was dependent on macrophages and NK cells; only NK cells showed direct cytotoxic activity.

Conclusions:

  • The combination of targeted liposomes and CpG-myb-as induces immune cell activation, contributing to antitumor activity against neuroblastoma.
  • Immune mechanisms, particularly macrophage and NK cell activation, are crucial for the observed therapeutic benefits.
  • This approach holds potential for enhancing the effectiveness of targeted liposome-based cancer therapies.

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...